<!DOCTYPE html>
<html>
<head>
<meta name="viewport" content="width=device-width, initial-scale=1">
<style>
a {
  text-decoration: none;
  display: inline-block;
  padding: 8px 16px;
}

a:hover {
  background-color: #ddd;
  color: black;
}

.previous {
  background-color: #f1f1f1;
  color: black;
}

</style>
</head>
<body>

<a href="index.html" class="previous">&laquo; Previous</a>
<!DOCTYPE html>
<html lang="en">
<head>
<title>CSS Template</title>
<meta charset="utf-8">
<meta name="viewport" content="width=device-width, initial-scale=1">
<style>
* {
  box-sizing: border-box;
}

body {
  font-family: Arial, Helvetica, sans-serif;
}

/* Style the header */
header {
  background-color: #1abc9c;
  padding: 30px;
  text-align: center;
  font-size: 35px;
  color: white;
}

/* Container for flexboxes */
section {
  display: -webkit-flex;
  display: flex;
  flex-direction:row;
}

/* Style the navigation menu */
nav {
  -webkit-flex: 1;
  -ms-flex: 1;
  flex: 1;
  background: linear-gradient(to bottom, #FFE53B 0%, #00FFFF 100%);
  padding: 20px;
}

/* Style the list inside the menu */
nav ul {
  list-style-type: none;
  padding: 0;
}

/* Style the content */
article {
  -webkit-flex: 3;
  -ms-flex: 3;
  flex: 3;
  padding: 10px;
}



/* Responsive layout - makes the menu and the content (inside the section) sit on top of each other instead of next to each other */
@media (max-width: 600px) {
  section {
    -webkit-flex-direction: column;
    flex-direction: column;
  }
}
/* Responsive for the div class of the image and the text */
html {
  box-sizing: border-box;
}
*, *:before, *:after {
  box-sizing: inherit;
}
body {
  margin: 0;
  background-color: #FFEEDD;
}
.textbox-1 {
  font-size: 1.25em;
  text-align: justify;
}
.row {
  display: flex;
  justify-content:space-around;
  padding:25px 0 ;
  max-width:1280px;
  margin:auto;
  
}
.flex {
  flex: 0 0 45%;
  background:#ccc;
}
.flex p{
  margin:0;
  padding:10px;
}
.object-fit{
  overflow:hidden;
  position:relative;
}
.object-fit img{
  position: absolute;
  top:50%;
  left:50%;
  height:auto;
  width:auto;
  min-width:50%;
  min-height:50%;
  transform:translate(-50%, -50%);
}
@supports (object-fit: cover) {
  .object-fit img  {
    position: absolute;
    left:0;
    top:0;
    height: 100%;
    width: 100%;
    transform: none;
    object-fit: cover;
  }
}
<!DOCTYPE html>
<html lang="en">
<head>
<title>CSS Template</title>
<meta charset="utf-8">
<meta name="viewport" content="width=device-width, initial-scale=1">
<style>
* {
  box-sizing: border-box;
}

body {
  font-family: Arial, Helvetica, sans-serif;
}

/* Style the header */
header {
  background-color: #1abc9c;
  padding: 30px;
  text-align: center;
  font-size: 35px;
  color: white;
}

/* Container for flexboxes */
section {
  display: -webkit-flex;
  display: flex;
  flex-direction:row;
}

/* Style the navigation menu */
nav {
  -webkit-flex: 1;
  -ms-flex: 1;
  flex: 1;
  background: linear-gradient(to bottom, #FFE53B 0%, #00FFFF 100%);
  padding: 20px;
}

/* Style the list inside the menu */
nav ul {
  list-style-type: none;
  padding: 0;
}

/* Style the content */
article {
  -webkit-flex: 3;
  -ms-flex: 3;
  flex: 3;
  padding: 10px;
}



/* Responsive layout - makes the menu and the content (inside the section) sit on top of each other instead of next to each other */
@media (max-width: 600px) {
  section {
    -webkit-flex-direction: column;
    flex-direction: column;
  }
}
/* Responsive for the div class of the image and the text */
html {
  box-sizing: border-box;
}
*, *:before, *:after {
  box-sizing: inherit;
}
body {
  margin: 0;
  background-color: #FFEEDD;
}
.textbox-1 {
  font-size: 1.25em;
  text-align: justify;
}
.row {
  display: flex;
  justify-content:space-around;
  padding:25px 0 ;
  max-width:1280px;
  margin:auto;
  
}
.flex {
  flex: 0 0 45%;
  background:#ccc;
}
.flex p{
  margin:0;
  padding:10px;
}
.object-fit{
  overflow:hidden;
  position:relative;
}
.object-fit img{
  position: absolute;
  top:50%;
  left:50%;
  height:auto;
  width:auto;
  min-width:70%;
  min-height:50%;
  transform:translate(-50%, -50%);
}
@supports (object-fit: cover) {
  .object-fit img  {
    position: absolute;
    left:0;
    top:0;
    height: 100%;
    width: 100%;
    transform: none;
    object-fit: cover;
  }
}
</style>
</head>
<body>
<header>
  <h2>Treatment</h2>
  
</header>

<section>
  <nav>
    <ul>
       <li><a href="treatment.html">Surgery</a></li>
      <li><a href="chemo.html">Chemotherapy</a></li>
      <li><a href="radio.html">Radiotherapy</a></li>
	  <li><a href="target.html">Targeted Therapy</a></li>
	  <li><a href="immuno.html">Immunotherapy</a></li>
    </ul>
  </nav>
  
  <article>
    <h1>Immunotherapy</h1>
	<p>Immunotherapy represents a significant advancement in the treatment of cervical cancer, leveraging the body's immune system to recognize and combat cancer cells. This approach is particularly relevant given the role of human papillomavirus (HPV) in the development of cervical cancer. 
</p>
<b><p>Types of Immunotherapy</p></b>
<b><p>Immune Checkpoint Inhibitors (ICIs)</p></b>
<b><p>Mechanism:</p></b> ICIs block proteins that inhibit immune responses, thereby enhancing T-cell activity against cancer cells.
<b><p>Key Drugs:</p></b>
<ul><li><b>Pembrolizumab (Keytruda):</b> An anti-PD-1 monoclonal antibody that has shown efficacy in treating recurrent or metastatic cervical cancer with PD-L1 expression.</li>
<li><b>Cemiplimab:</b> Another anti-PD-1 therapy demonstrating significant overall survival improvement in clinical trials.</li></ul>
<b><p>Clinical Trials:</p></b> Trials such as KEYNOTE-028 and EMPOWER-Cervical 1 have established the effectiveness of these agents, with response rates observed in patients with PD-L1-positive tumors.
<b><p>Therapeutic Vaccines</p></b>
<b><p>Mechanism:</p></b> These vaccines aim to elicit a strong immune response specifically targeting HPV antigens, particularly E6 and E7 oncoproteins.
<b><p>Examples:</p></b>
<b><p>ADXS11-001:</p></b> An attenuated Listeria monocytogenes vaccine targeting HPV16 E7, currently undergoing Phase 3 trials.
<b><p>HB-201 and HB-202:</p></b> Viral vector-based vaccines targeting HPV16 E6/E7 in early-phase trials.
<b><p>Potential:</p></b> These vaccines not only aim to treat existing cancers but also hold promise for preventing the progression of precancerous lesions (CIN).
<b><p>Adoptive Cell Therapy (ACT)</p></b>
<b><p>Mechanism:</p></b></p></b> ACT involves extracting T cells from a patientâ€™s tumor, expanding them in vitro, and reintroducing them to enhance the immune response against tumor cells.
<b><p>Focus:</p></b> Tumor-infiltrating lymphocytes (TILs) are selected based on their reactivity to HPV antigens, aiming to boost the anti-tumor response.
<b><p>Combination Therapies</p></b>
Combining ICIs with chemotherapy or other immunotherapies is being explored to enhance efficacy. For instance, combining pembrolizumab with platinum-based chemotherapy has shown promising results in clinical settings.
<a href="https://www.cancer.gov/types/cervical/treatment">Source</a>
  </article>
</section>

</body>
</html>





































